← Back to Home

Early trial of Huntington’s disease drug brezosiran: disease-causing protein in cerebrospinal fluid falls by about 60%

After a single dose, brezosiran significantly reduced mutant huntingtin protein in the highest-dose group, providing human evidence for a gene-silencing therapy. Whether this change can translate into slower disease progression will be the key question for the next stage of trials.

By SURL BioNews

For people with Huntington’s disease, reducing the disease-causing protein is one therapeutic approach aimed at stopping the continued loss of neurological function. On October 23, Alnylam announced preliminary Phase 1b results for its experimental drug brezosiran: patients who received the highest dose evaluated so far had an average reduction of about 60% in mutant huntingtin protein in their cerebrospinal fluid after three months. However, a reduction in protein levels does not yet demonstrate that patients’ motor function, cognition or ability to carry out daily activities is protected as a result.

The results were presented at the 2026 European Huntington’s Disease Network Clinical Research Congress. The trial used a randomized, double-blind, placebo-controlled design, and the current data cover 48 participants across five single-dose cohorts. Participants were aged 25 to 70, had a genetically confirmed diagnosis, and were in HD-ISS Stage 2 or early Stage 3. The study focused on safety, tolerability and whether the drug reduced the target protein.

The research team observed greater reductions in cerebrospinal fluid mutant huntingtin protein as the dose increased. In the highest-dose group, the average reductions at three months were 60% and 64%; STAT reported that the two figures came from different testing methods, rather than two treatment groups. These data support that the drug has produced its intended biological effect, but cannot be directly translated into the degree of protection afforded to neurons in the brain.

Brezosiran, also known as ALN-HTT02, is an RNA interference drug delivered into the cerebrospinal fluid by intrathecal injection. It targets a sequence in exon 1 of huntingtin messenger RNA, reducing production upstream in the protein-making process. According to Alnylam’s design, this target site allows it to address both full-length mutant protein and the shorter HTT1a form; however, whether targeting these forms can deliver better clinical outcomes remains unresolved.

On safety, the company said some participants had been followed for up to 12 months, with no dose-dependent increases observed during that period in cerebrospinal fluid inflammatory markers, neurofilament light chain or ventricular volume. These observations provide early safety signals, but cannot rule out risks that are less common, delayed or emerge only after repeated dosing; the ability of a small trial to detect such risks remains limited.

To determine how long the effects last, eligible participants may enter an open-label extension study, receiving brezosiran once every six months for up to 36 months of treatment to assess long-term safety, the durability of protein reduction and exploratory measures of disease progression. Dosing once every six months remains an investigational schedule and is not yet an established treatment regimen.

Alnylam plans to launch a placebo-controlled pivotal trial in 2027, but must first reach agreement with regulators on the study plan. The next stage will move from asking “Can it reduce the disease-causing protein?” to “Can it slow disease progression?” For patients, bridging the gap between these two questions is the most important test of this therapy.

References

  1. Alnylam Pharmaceuticals
  2. Alnylam Pharmaceuticals — Capella
  3. STAT
  4. RTTNews